Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.
Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.
First-line therapy for renal cell carcinoma has primarily been tyrosine kinase inhibitors that target vascular endothelial growth factor and other receptors.
The authors say there s an urgent need for HER2-positive breast cancer drugs that cross the blood–brain barrier. The study was published as a preprint and has not yet been peer reviewed.
Many drugs with accelerated approvals lack high added value compared with other therapies, and conducting further trials of these drugs is financially risky for the manufacturers.